Pharmacovigilance Trends Shaping Drug Safety Reporting in 2026

Pharmacovigilance trends in 2026 shows more connected, data-led safety surveillance, but persistent underreporting and fragmented information still limit the industry's view of medicine-related risk.

As MedSafety Week runs from 2 to 8 November, pharmaceutical companies face a broader challenge of turning reports, clinical records, and real-world data into timely, reliable safety decisions across the medicine lifecycle.

Image

Why Pharmacovigilance Needs a Wider Evidence Base

Pharmacovigilance (PV) covers the detection, assessment, understanding, and prevention of adverse effects associated with medicines and vaccines.

Its remit extends from Clinical Development into post-authorisation use, when larger and more diverse patient populations can reveal risks that were not apparent during trials.

Clinical trials remain essential to the initial benefit-risk assessment. However, their size, duration, eligibility criteria, and controlled conditions limit the safety evidence they can generate.

Rare adverse drug reactions (ADRs), delayed effects, drug-drug interactions, and risks in under-represented populations may only become visible after broader exposure.

Post-marketing surveillance therefore depends on several evidence streams.

These include spontaneous individual case safety reports (ICSRs), clinical and observational studies, electronic health records (EHRs), registries, literature, patient support programmes, and other sources of real-world data (RWD).

Each source offers a different view.

Spontaneous reports can identify unexpected patterns, while longitudinal healthcare data can help assess exposure, outcomes and background incidence. Clinical trial safety data provide structured evidence within a defined protocol and population.

The value of the post-marketing surveillance data lies in interpreting these sources together, while accounting for their different limitations.

Underreporting remains a major weakness. The Uppsala Monitoring Centre (UMC), which coordinates the annual global MedSafety Week campaign, states that fewer than ten per cent of suspected side effects are reported.

Missing reports can delay recognition of risks and can leave regulators and marketing authorisation holders (MAHs) with an incomplete picture of medicine use.

The 2026 campaign theme, Side effects: Don't ignore them, report them, places reporting responsibility across patients, caregivers and healthcare professionals.

For industry, the message also has operational significance. A safety system can only assess information that enters its processes, and reporting quality affects the evidence available for signal evaluation.

The challenge is particularly relevant for products used across multiple indications, treatment settings, and patient groups. As exposure expands, the volume and diversity of safety information grow. PV teams must process that information without losing context, traceability, or the ability to distinguish a genuine signal from reporting artefacts.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Which Pharmacovigilance Trends Are Reshaping Safety Surveillance in 2026?

In 2026, pharmacovigilance trends span several areas of development, including artificial intelligence (AI), automation, RWD, digital reporting, patient participation, international harmonisation, and advanced analytical tools.

These themes reflect a wider shift from predominantly reactive case collection towards more continuous and integrated safety surveillance.

AI and machine learning for detection

AI and machine learning can help PV teams analyse large datasets, identify patterns, and prioritise information for further assessment.

Natural language processing can extract relevant details from free-text narratives, medical notes, and literature, where important safety information may not appear in structured fields.

The World Health Organization (WHO) identifies AI, machine learning, and natural language processing among the tools being explored for pharmacovigilance.

The WHO’s global monitoring ecosystem includes VigiBase, which contains more than 36 million individual case safety reports, alongside analytical and reporting tools developed by UMC.

These technologies may reduce manual processing and help teams identify relationships that warrant investigation.

However, they do not, by themselves, establish causality or confirm a safety signal. Model performance depends on source data quality, coding consistency, population coverage, and the clinical context available to the system.

Automation changes case processing

Automation is being applied to activities such as intake, duplicate detection, data extraction, coding support, case triage, and report preparation.

These tasks can consume significant operational capacity, particularly for organisations managing high case volumes across regions and products.

The benefit is greatest when automation reduces repetitive handling while preserving review controls.

Poorly configured systems can propagate incorrect data, misclassify events, or obscure the rationale behind a decision.

Efficiency must therefore be assessed alongside case quality, auditability, and escalation performance.

Real-world data extends the safety picture

RWD from EHRs, claims databases, disease registries, and other healthcare sources can support safety assessment beyond spontaneous reporting.

These datasets may help researchers examine longer-term outcomes, utilisation patterns, comorbidities, and risks in populations that clinical trials do not fully represent.

The European Medicines Agency (EMA) has expanded its use of RWD through the Data Analysis and Real World Interrogation Network (DARWIN EU).

By 2026, DARWIN EU had access to data from approximately 250 million patients through around 40 data partners. Its work supports regulatory questions across medicine use, safety, and effectiveness.

The scale of the network is significant, but volume alone does not create reliable evidence. Coding differences, missing variables, confounding, incomplete follow-up, and uneven data access can affect interpretation.

Therefore, in clinical trials, sponsors and regulators need fit-for-purpose study designs and transparent analytical methods.

Digital reporting brings patients closer to surveillance

Mobile applications, online portals, and patient support programmes create additional routes for reporting suspected adverse reactions.

They can make reporting more accessible and capture experiences that may not reach a healthcare professional during a consultation.

However, digital access does not automatically improve report quality. Organisations must consider duplicate submissions, incomplete narratives, identity verification, data privacy, and the processes used to follow up missing information.

Image

Global standards and patient participation gain importance

International harmonisation supports more consistent safety data management across jurisdictions.

The ICH E2D(R1) guideline, which came into effect in the European Union on 18 March 2026, updates post-approval safety data definitions and reporting standards. It addresses increasingly used information sources, including social media, market research programmes, and patient support programmes.

The U.S. Food and Drug Administration (2026) also introduced final guidance to implement ICH E2D(R1) in March 2026.

The guidance ensures safety information now arrives through channels that were less prominent when the earlier guidance was written.

Companies now need clear procedures for identifying reportable information, documenting receipt, and applying the relevant regulatory timelines.

What These Pharmacovigilance Changes Mean for Clinical Development

PV is often associated with post-marketing surveillance, but its foundations are established much earlier.

Clinical trials generate the initial structured safety dataset, including adverse event records, serious adverse event reports, laboratory findings, investigator assessments, and safety narratives.

The quality of this information affects both ongoing trial oversight and later evaluation of the product’s safety profile.

Sponsors should therefore treat safety data as a lifecycle asset.

Consistent terminology, clear source documentation, and reliable reconciliation between clinical and safety systems support more effective review.

When safety information moves between sites, contract research organisations (CROs), laboratories, and PV vendors, responsibility for data quality and escalation must remain clear.

This is especially important when companies outsource case processing or safety operations. Delegation does not remove sponsor accountability.

Pharmatica’s Insights into CRO and vendor oversight examines the governance expectations that apply to outsourced trial activities. Similar discipline is needed across PV arrangements, where vendor performance can affect case completeness, submission timelines, and inspection readiness.

The revised ICH E2D(R1) framework also gives companies a reason to review how they capture information from newer sources.

Patient support programmes and market research activities may generate safety information that requires assessment under applicable reporting rules. Social media monitoring raises further questions about source verification, minimum case information, follow-up, and documentation.

For clinical development teams, the practical implications include:

• Connecting safety and clinical data processes: Define how adverse event information moves between clinical databases, safety systems, and medical review.
• Reviewing vendor responsibilities: Confirm who identifies, forwards, assesses, reconciles, and reports safety information, including information from subcontractors.
• Strengthening source quality: Improve training and reporting pathways for investigators, site staff, patients, and caregivers.
• Assessing digital and AI tools: Establish performance measures, human review requirements, audit trails, and escalation criteria before deployment.
• Using RWD with defined questions: Select data sources and methods that can address a specific safety uncertainty, rather than treating larger datasets as inherently better evidence.

These priorities also intersect with trial design. Protocols need clear adverse event collection and reporting requirements, while safety monitoring plans should reflect the product, patient population and known risks.

Pharmatica’s coverage of clinical trial protocol amendments explores why changes to trial procedures require a documented scientific and operational rationale. New safety information may justify an amendment, but the decision must preserve participant protection and the interpretability of trial results, especially through Data Monitoring Committee activities.

The EMA’s AI workplan for 2025–2028 also shows that regulators are also building capacity to assess AI across the medicine lifecycle. Its priorities include policy, tools, collaboration and structured experimentation.

For sponsors, this reinforces the need to govern AI according to its intended use and potential impact, rather than treating it as an ordinary software purchase.

Read The Looming Threat of Geopolitical Risk in Clinical Supply Chains

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Image

Where the Pharmacovigilance Activities Still Fall Short

The transition to data-driven PV is not simply a matter of implementing new technologies.

Challenges in data privacy, reporting variability, and building IT infrastructure persist. Each can limit the value of otherwise sophisticated surveillance tools.

Underreporting remains a foundational weakness. AI cannot reliably detect patterns in information that has never been collected.

Reporting campaigns, accessible channels, and professional awareness remain essential, particularly in regions where PV infrastructure and specialist resources are limited.

Data fragmentation presents another significant limitation.

Clinical records, spontaneous reports, claims data, and patient-generated information use different formats and levels of detail. Linking them can introduce duplication, inconsistent coding and uncertainty about exposure or outcomes.

Data standardisation helps, but it does not remove the need for clinical interpretation and medical expertise.

AI also introduces specific risks. Models may reproduce biases in their training data, miss rare events, or generate classifications that appear credible but lack sufficient evidence.

Therefore, PV teams need documented validation, ongoing performance monitoring, change control, and human oversight. They should also establish how teams will investigate errors and record decisions.

Privacy and cross-border data access require equal attention. RWD programmes must operate within applicable data protection frameworks, governance arrangements, and permissions.

Privacy-preserving analysis can widen access to useful datasets, but organisations still need to demonstrate that data use is lawful, proportionate, and secure.

Finally, more signals do not automatically mean better decisions. Disproportionality analyses and machine-generated alerts can identify associations that require investigation, but they may also generate false positives.

PV teams must assess biological plausibility, temporal relationships, alternative explanations, exposure, confounding, and the totality of available evidence.

The strategic test is whether new tools improve the quality and timeliness of safety decisions.

Faster case processing has limited value if it creates more rework or weakens the evidence trail. Larger datasets matter when they answer relevant questions.

Automation therefore matters when it frees qualified professionals to focus on assessment, not when it removes necessary judgement.

Pharmatica has also examined the implications of GVP Module III Revision 2, which raises expectations around pharmacovigilance oversight and subcontracting.

The wider lesson is that technology and outsourcing can change how work is performed, but they do not remove the need for documented accountability.

Image

MedSafety Week 2026 Puts Reporting Back at the Centre

MedSafety Week 2026 is a reminder that the pharmacovigilance system begins with recognising and reporting suspected adverse reactions.

The message applies across the medicine lifecycle, from clinical trials to routine use, and depends on the participation of patients, caregivers, and healthcare professionals.

The latest pharmacovigilance trends offer companies more ways to collect, process, and analyse safety information.

AI, automation, RWD, and digital reporting can extend surveillance capacity, while updated international standards provide a framework for handling newer information sources. Their value will depend on the quality of the underlying data and the governance surrounding their use.

For sponsors, the priority is to connect these capabilities to established clinical and regulatory responsibilities. That means investing in reporting quality, clear vendor oversight, fit-for-purpose data systems and expert review.

It also means measuring whether new approaches improve signal assessment and support better benefit-risk decisions.

Modern pharmacovigilance is more data-rich, but its effectiveness still depends on the quality of the evidence entering the system and the judgement applied to it.

The organisations that connect reporting, Clinical Development, and post-authorisation surveillance will be better placed to identify emerging risks and respond with appropriate action.

Pharmatica examines the Preclinical Science, Regulation, and Technical Operational decisions shaping Clinical Development and medicine safety. Our Insights connect emerging Technologies with the responsibilities that determine whether they deliver meaningful value for patients and the pharmaceutical industry.

Pharmatica: Insight. Connection. Impact.